Office Of Regulatory Affairs Faces Training, Retirement Challenges
This article was originally published in The Gray Sheet
With better funding than ever for enforcement activities, FDA's Office of Regulatory Affairs is looking to new challenges, including training an influx of new investigators and adjusting to the retirement of its most experienced staffers
You may also be interested in...
FDA Commissioner Margaret Hamburg is honing the agency's enforcement system to get warning letters out faster and create a formal "close-out" process that publicly indicates when a firm has addressed FDA's concerns
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.